By Colin Kellaher
Biogen and Stoke Therapeutics have agreed to collaborate on Stoke's proposed zorevunersen treatment for the severe genetic epilepsy Dravet syndrome in a deal potentially worth hundreds of millions of dollars to Stoke.
The biotechnology companies on Tuesday said they will work together to develop and commercialize zorevunersen outside of North America, with Biogen making an upfront payment of $165 million to Stoke.
As part of the agreement, Cambridge, Mass.-based Biogen will receive exclusive rest-of-world commercialization rights to zorevunersen, while Stoke, based in Bedford, Mass., retains exclusive rights the U.S., Canada and Mexico, the companies said.
Stoke is also eligible for up to $385 million in development and commercial milestone payments, along with royalties on potential sales in Biogen's territory.
The companies said Biogen will also chip in 30% of external clinical development costs for zorevunersen, a potential first-in-class disease-modifying medicine for Dravet syndrome, a genetic disorder characterized by severe, recurrent seizures as well as significant cognitive and behavioral impairments.
Stoke is on track to launch a global Phase 3 registrational study of zorevunersen in the second quarter, with a pivotal data readout expected in the second half of 2027 that is expected to support global regulatory filings, the companies said.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 18, 2025 08:55 ET (13:55 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.